TG01 / GMCSF in combination with Gemcitabine

Hyggelige
10.04.2018 kl 00:00 728

Dette er en arkivert tråd!

Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

32 participants

-Estimated Primary Completion Date : June 2018

-Estimated Study Completion Date : June 2018

https://clinicaltrials.gov/ct2/show/NCT02261714

-------------------

Targovax reports positive survival data from Phase I/II trial of TG01 in pancreatic cancer

https://www.drugdevelopment-technology.com/news/newstargovax-reports-positive-survival-data-from-phase-iii-trial-of-tg01-in-pancreatic-cancer-5731169/


2018 blir jo et veldig spennende år i alle fall.
Arkivert